Point72 Asset Management
OREX

Point72 Asset Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Point72 Asset Management’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-204,830
Closed -$16M – 965
2015
Q1 		$16M Buy
+204,830
New +$12.7M 0.11% 241

Other funds holding OREX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Point72 Asset Management's OREX Position: Q2 2015 in Review

Point72 Asset Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2015, closing a stake of 204,830 shares — an estimated $16M sold.

Point72 Asset Management first reported a position in OREX in Q1 2015 and held it in 1 quarter. The position peaked at $16M in Q1 2015. 161 funds tracked by Wall St. Rank hold OREX as of Q2 2015.

  • Point72 Asset Management reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • Point72 Asset Management sold 204,830 Orexigen Therapeutics, Inc. shares in Q2 2015, an estimated $16M.
  • Point72 Asset Management first reported a position in Orexigen Therapeutics, Inc. in Q1 2015 and held it in 1 quarter.
  • Point72 Asset Management's Orexigen Therapeutics, Inc. position peaked at $16M in Q1 2015.
  • 161 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2015.

Based on Point72 Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.